Clinical trials
Telitacicept clinical trials
Below are recruiting telitacicept clinical trials, each written for real people, not researchers. We’re tracking 19 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05680480RecruitingPhase 2
Telitacicept for active lupus kidney inflammation
This trial tests telitacicept to improve lupus nephritis (inflammation of the kidneys caused by lupus). It targets people with active kidney disease confirmed by biopsy and compares outcomes while you receive standard steroid plus mycophenolate treatment.
Hefei, AnhuiAges 18–75 - NCT05962840RecruitingPhase 4
Rituximab plus telitacicept for ANCA vasculitis
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
BeijingAges 18–65 - NCT06125405RecruitingPhase 3
Telitacicept for children with frequently relapsing nephrotic syndrome
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hangzhou, ZhejiangAges 2–18 - NCT06549959RecruitingPhase 1
Study of telitacicept injection in healthy volunteers
This trial tests a new way to give a drug called telitacicept, comparing a pre-filled injector to the standard powder version. It helps researchers understand how the drug works in the body.
Guiyang, GuizhouAges 18–50 - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70 - NCT06979271Recruiting
Testing a new drug combo for tough rheumatoid arthritis
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
Hangzhou, ZhejiangAges 18–85 - NCT07404865RecruitingPhase 3
Telitacicept for active primary Sjögren's disease
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
Chandler, ArizonaAges 18–75 - NCT05965284RecruitingPhase 4
Telitacicept to help keep ANCA vasculitis in remission
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
Beijing, Beijing MunicipalityAges 18–65 - NCT05998759RecruitingPhase 2
Telitacicept for low platelets from connective tissue disease
This trial tests a new medicine called telitacicept for people with connective tissue disease (like lupus or Sjögren's) whose platelet counts stay dangerously low despite standard treatments. It aims to raise platelet levels and reduce bleeding risk.
Hefei, AnhuiAges 18–75 - NCT06375005RecruitingPhase 2
Telitacicept for early diffuse scleroderma
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Yangzhou, JiangsuAges 18–70 - NCT06394063Recruiting
Telitacicept to prevent lupus flares
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
ShanghaiAges 18–70 - NCT06456580RecruitingPhase 3
Telitacicept for generalized myasthenia gravis
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Scottsdale, ArizonaAges 18 years+ - NCT06546540RecruitingPhase 4
Testing telitacicept for systemic sclerosis safety and effectiveness
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
BeijingAges 18 years+ - NCT07077486RecruitingPhase 4
Testing telitacicept vs cyclophosphamide for lupus lung disease
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Wuhan, HubeiAges 18–80 - NCT07249632RecruitingPhase 3
Study of Telitacicept for Eye Muscle Weakness from Myasthenia Gravis
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
Beijing, Beijing MunicipalityAges 12–80 - NCT07340463RecruitingPhase 2
Biologics vs standard therapy for lupus kidney disease
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Nanjing, JiangsuAges 14–65 - NCT07491016Recruiting
Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hangzhou, ZhejiangAges 18–85 - NCT07522099RecruitingPhase 2
Study of ADARx Treatment for Kidney Disease in Chinese Adults
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Shenzhen, GuangdongAges 18 years+ - NCT06458972Recruiting
Telitacicept for lupus: safety and effectiveness trial
This trial tests a new biologic drug called telitacicept for people with systemic lupus erythematosus (SLE). It aims to see how safe and effective the drug is and may offer a new treatment option for lupus.
Wuhan, HubeiAges 18–70
Hear when a new Telitacicept trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for telitacicept?
- Yes. Clin2 currently lists 19 recruiting telitacicept studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a telitacicept trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a telitacicept trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.